Nkarta (NKTX) 25th Annual Needham Virtual Healthcare Conference summary

Strategic pivot and technology overview

• Shifted focus from oncology to autoimmune diseases, leveraging CD19-directed CAR-NK cells for B-cell-mediated conditions.

• NK cells are allogeneic, off-the-shelf, and have a finite lifespan, allowing for on-demand dosing without apheresis.

• Early data suggest only initial B-cell depletion is needed for immune reset, aligning with NK cell pharmacokinetics.

• Safety profile in autoimmune settings is favorable, with no life-threatening CRS or ICANS observed in over 30 patients.

• Lead program is engineered with membrane-bound IL-15 to enhance persistence and is being tested across multiple autoimmune indications.

Market sentiment and clinical data landscape

• Investor sentiment in cell therapy for autoimmune disease has softened due to limited robust data and excitement around new modalities.

• Maturity of data sets is expected to improve by 2026, with more comprehensive results anticipated at major conferences.

• Recent positive data from competitors have reignited some investor interest.

• Early studies often had small patient numbers and short follow-up, but benchmarks are shifting as larger, longer-term data emerge.

• Real-world expectations are being recalibrated as company-sponsored, multi-center trials yield more heterogeneous results.

Clinical development and operational updates

• Two main company-sponsored INDs: INTRUST-1 (lupus nephritis, primary membranous nephropathy) and INTRUST-2 (systemic sclerosis, myositis, ANCA-associated vasculitis, and now rheumatoid arthritis).

• Two investigator-sponsored trials in systemic lupus and myasthenia gravis.

• Initial data update planned for later this year, with a focus on narrowing to one or two lead indications for further development.

• Enrollment improved after switching to full lymphodepletion (fludarabine and cyclophosphamide), reflecting increased rheumatologist comfort.

• Outpatient dosing now possible, expanding access beyond traditional cell therapy centers.